A Disability Bioethics Reading of the FDA and EMA Evaluations on the Marketing Authorisation of Growth Hormone for Idiopathic Short Stature Children

The diagnosis of idiopathic short stature (ISS) refers to children who are considerably shorter than average without any identified medical reason. The US Food and Drug Administration (FDA) authorised marketing of recombinant human growth hormone (hGH) for ISS in 2003, while the European Medicines A...

Descripción completa

Detalles Bibliográficos
Autor principal: Murano, Maria Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411515/
https://www.ncbi.nlm.nih.gov/pubmed/32056083
http://dx.doi.org/10.1007/s10728-020-00390-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411515/
https://www.ncbi.nlm.nih.gov/pubmed/32056083
http://dx.doi.org/10.1007/s10728-020-00390-1

Ejemplares similares